The goal of the Centralized Histopathology Laboratory (CHPL) is to provide histologic services to investigators at M.D. Anderson Cancer Center. The CHPL supplies technical support and consultation, develops or applies appropriate techniques, and maintains the consistency and high quality needed to perform these techniques. The CHPL is currently located in the Department of Pathology in 375 feet/2. Because of the increasing emphasis on in vivo systems in cancer biology and developmental biology, the number of laboratories using tissue specimens, transgenic mice, and gene-knockout technologies has increased dramatically. To provide efficient histology services to the institution, the CHPL will be expanded, and a second 370- feet/2 laboratory will be located in the R.E. """"""""Bob"""""""" Smith Research Building. The well-equipped and well-staffed CHPL processes fixed and frozen specimens for routine histologic analysis, immunohistochemical in situ hybridization (colorimetric procedures), and special staining for tissue sections and cells. The CHPL (both sites) is directed by Dr. Isaiah J. Fidler, and is accessible to all faculty, at M.D. Anderson Cancer Center, will preference given to investigators with peer-reviewed grants. Among the services provided are rapid preparation of high-quality standard histologic sections; application of special technologies as the need arises for selected projects, including preparation of frozen sections and histochemical, immunohistochemical, and tissue sections for in situ hybridization analysis; consultation with investigators to tailor technology to their special needs; and interpretation of histologic data. To access the CHPL, investigators make a formal application. After approval by the Director, the histotechnologist meets with the investigators to determine special needs of the study and the technical staff provides the histopathological services. The services are prioritized and coordinated to provide timely service. The development of new technologies that require additional equipment or special supplies has been funded by M.D. for specialized procedures such as in situ hybridization and 500 specially stained slides yearly. The increase in studies of transgenic mice and gene knockout mice will significantly increase the CHPL's workload, especially for special preparations such as serial sections of whole-embryos mounts. The CHPL is an essential component of the M.D. Anderson centralized research facilities that require histologic analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-26S2
Application #
6506678
Study Section
Project Start
2001-09-28
Project End
2002-06-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360
Ellrott, Kyle; Bailey, Matthew H; Saksena, Gordon et al. (2018) Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6:271-281.e7
White, Matthew C; Schroeder, Rebecca D; Zhu, Keyi et al. (2018) HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene 37:4413-4427
Abaza, Yasmin; Hidalgo-Lopez, Juliana E; Verstovsek, Srdan et al. (2018) Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85
McGrail, Daniel J; Federico, Lorenzo; Li, Yongsheng et al. (2018) Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9:1317
Li, Carrie J; Jiang, Changying; Liu, Yang et al. (2018) Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther :
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Raber, Benjamin; Bea, Vivian J; Bedrosian, Isabelle (2018) How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am 26:281-288
Li, Roger; Metcalfe, Michael J; Ferguson 3rd, James E et al. (2018) Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121:244-251

Showing the most recent 10 out of 12418 publications